AT366026B - Verfahren zur herstellung von neuen peptiden - Google Patents

Verfahren zur herstellung von neuen peptiden

Info

Publication number
AT366026B
AT366026B AT0213878A AT213878A AT366026B AT 366026 B AT366026 B AT 366026B AT 0213878 A AT0213878 A AT 0213878A AT 213878 A AT213878 A AT 213878A AT 366026 B AT366026 B AT 366026B
Authority
AT
Austria
Prior art keywords
producing new
new peptides
peptides
producing
new
Prior art date
Application number
AT0213878A
Other languages
German (de)
English (en)
Other versions
ATA213878A (de
Original Assignee
Salk Inst For Biological Studi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Salk Inst For Biological Studi filed Critical Salk Inst For Biological Studi
Publication of ATA213878A publication Critical patent/ATA213878A/de
Application granted granted Critical
Publication of AT366026B publication Critical patent/AT366026B/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/655—Somatostatins
    • C07K14/6555—Somatostatins at least 1 amino acid in D-form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/16—Somatostatin; related peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/26—Containing cys-cys disulfide bridge between nonadjacent cysteine residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT0213878A 1977-03-28 1978-03-24 Verfahren zur herstellung von neuen peptiden AT366026B (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US05/781,580 US4105603A (en) 1977-03-28 1977-03-28 Peptides which effect release of hormones

Publications (2)

Publication Number Publication Date
ATA213878A ATA213878A (de) 1981-07-15
AT366026B true AT366026B (de) 1982-03-10

Family

ID=25123228

Family Applications (1)

Application Number Title Priority Date Filing Date
AT0213878A AT366026B (de) 1977-03-28 1978-03-24 Verfahren zur herstellung von neuen peptiden

Country Status (19)

Country Link
US (1) US4105603A (enExample)
JP (1) JPS53130687A (enExample)
AT (1) AT366026B (enExample)
AU (1) AU519122B2 (enExample)
BE (1) BE865380A (enExample)
CA (1) CA1102314A (enExample)
CH (1) CH639361A5 (enExample)
DE (1) DE2813327A1 (enExample)
DK (1) DK131878A (enExample)
ES (1) ES468241A1 (enExample)
FI (1) FI780907A7 (enExample)
FR (1) FR2385688A1 (enExample)
GB (1) GB1564191A (enExample)
IE (1) IE46862B1 (enExample)
IT (1) IT1105152B (enExample)
LU (1) LU79320A1 (enExample)
NL (1) NL7803289A (enExample)
SE (1) SE446190B (enExample)
ZA (1) ZA781599B (enExample)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4211693A (en) * 1977-09-20 1980-07-08 The Salk Institute For Biological Studies Peptides with para-substituted phenylalanine
US4185010A (en) * 1978-12-12 1980-01-22 American Home Products Corporation Nonapeptides
US4225472A (en) * 1979-05-29 1980-09-30 American Home Products Corporation Truncated somatostatin analogs
USRE30548E (en) * 1979-08-31 1981-03-17 The Salk Institute For Biological Studies Peptides which effect release of hormones
DE19375086I2 (de) * 1979-11-27 2003-01-09 Novartis Ag Polypeptide Verfahren zu ihrer Herstellung pharmazeutische Zusammensetzungen die diese Polypeptide enthalten und ihre Verwendung
FR2523125A1 (fr) * 1982-03-08 1983-09-16 Sanofi Sa Analogues de la somatostatine a activite biologique modifiee et medicaments en contenant
US4428942A (en) 1982-05-17 1984-01-31 The Salk Institute For Biological Studies Analogs of somatostatin
US4443368A (en) * 1982-11-01 1984-04-17 The Salk Institute For Biological Studies Peptides affecting gonadal function
US4880778A (en) * 1986-05-12 1989-11-14 Eastman Kodak Company Combinations having synergistic growth hormone releasing activity and methods for use thereof
US4839344A (en) * 1987-06-12 1989-06-13 Eastman Kodak Company Polypeptide compounds having growth hormone releasing activity
US4880777A (en) * 1987-09-01 1989-11-14 Eastman Kodak Company Synthetic peptides having growth hormone releasing activity
AU637316B2 (en) * 1988-01-28 1993-05-27 Eastman Kodak Company Polypeptide compounds having growth hormone releasing activity
US6737408B1 (en) 1997-08-07 2004-05-18 University Of Cincinnati Compounds for control of appetite, blood pressure, cardiovascular response, libido, and circadian rhythm
EP1203014B1 (en) * 1999-08-06 2004-10-13 Genentech, Inc. Peptide antagonists of factor viia
US20040001827A1 (en) * 2002-06-28 2004-01-01 Dennis Mark S. Serum albumin binding peptides for tumor targeting
EP1757311B1 (en) 1999-12-24 2009-02-11 Genentech, Inc. Methods and compositions for prolonging elimination half-times of bioactive compounds
US20060228364A1 (en) * 1999-12-24 2006-10-12 Genentech, Inc. Serum albumin binding peptides for tumor targeting
US20050287153A1 (en) * 2002-06-28 2005-12-29 Genentech, Inc. Serum albumin binding peptides for tumor targeting
ES2270893T3 (es) 1999-12-24 2007-04-16 Genentech, Inc. Procedimiento y composiciones para prolongar la vida media de compuestos bioactivos.
US7164002B2 (en) 2002-02-06 2007-01-16 Genentech, Inc. FVIIa antagonists
CN101048425B (zh) * 2003-09-18 2012-12-26 雷文生物技术公司 Kid3及与其结合的kid3抗体
JP4390568B2 (ja) * 2004-01-19 2009-12-24 富士通株式会社 遅延測定システム
KR101295139B1 (ko) * 2004-06-07 2013-08-12 레이븐 바이오테크놀로지스, 인코퍼레이티드 트랜스페린 리셉터 항체
BRPI0516577A (pt) * 2004-10-05 2008-09-16 Genentech Inc agentes terapêuticos com toxicidade diminuìda
US7687242B2 (en) * 2005-01-12 2010-03-30 Raven Biotechnologies, Inc. KID31 and antibodies that bind thereto
JP2008538173A (ja) * 2005-01-31 2008-10-16 レイベン バイオテクノロジーズ，インコーポレイティド Ｌｕｃａ２およびそれに結合する抗体
WO2006084075A2 (en) 2005-02-02 2006-08-10 Raven Biotechnologies, Inc. Adam-9 modulators
US20060171952A1 (en) * 2005-02-02 2006-08-03 Mather Jennie P JAM-3 and antibodies that bind thereto
EP1846455A4 (en) * 2005-02-03 2010-02-17 Raven Biotechnologies Inc ANTIBODY TO THE ONKOSTATIN M RECEPTOR
US20070197445A1 (en) * 2006-01-18 2007-08-23 University Of Cincinnati Compounds for control of appetite
WO2008066691A2 (en) * 2006-11-08 2008-06-05 Macrogenics West, Inc. Tes7 and antibodies that bind thereto
ES2414879T4 (es) 2009-04-20 2013-10-30 Allergan, Inc. Hidrogeles de fibroína de seda y usos de éstos
PL219569B1 (pl) 2010-02-19 2015-05-29 Peptaderm Spółka Z Ograniczoną Odpowiedzialnością Cykliczne tetrapeptydy i ich zastosowanie
PH12012501751A1 (en) 2010-03-04 2012-11-12 Macrogenics Inc Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
ME03447B (me) 2010-03-04 2020-01-20 Macrogenics Inc Anтitela reakтivna sa b7-нз, njihovi imunološki akтivni fragmenтi i upotreba
MX369220B (es) 2011-05-21 2019-10-31 Macrogenics Inc Moleculas que enlazan cd3 capaces de enlazar a cd3 humano y no humano.
KR20140068087A (ko) 2011-08-23 2014-06-05 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 펩티드 나노입자 및 이의 용도
US9487587B2 (en) 2013-03-05 2016-11-08 Macrogenics, Inc. Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof
BR112015022790A8 (pt) 2013-03-14 2020-01-21 Univ Duke molécula biespecífica, composição farmacêutica, método de tratamento de uma infecção por vírus latente em um indivíduo em necessidade de tal tratamento, método de tratamento de uma infecção por vírus persistente em um indivíduo em necessidade de tal tratamento, método de tratamento de uma infecção por vírus inativo em um indivíduo em necessidade de tal tratamento, método para exterminar uma célula que contém um genoma viral, e, método para exterminar uma célula que expressa uma proteína viral
CA2911613A1 (en) 2013-03-29 2014-10-02 Centre National De La Recherche Scientifique (Cnrs) Cgrp receptor agonist for hiv treatment or prevention
WO2015184207A1 (en) 2014-05-29 2015-12-03 Macrogenics, Inc. Tri-specific binding molecules that specifically bind to multiple cancer antigens and methods of use thereof
SG11201702544WA (en) 2014-09-29 2017-04-27 Univ Duke Bispecific molecules comprising an hiv-1 envelope targeting arm
RU2017129236A (ru) 2015-01-26 2019-03-07 Макродженикс, Инк. Мультивалентные молекулы, содержащие dr5-связывающие домены
TWI773646B (zh) 2015-06-08 2022-08-11 美商宏觀基因股份有限公司 結合lag-3的分子和其使用方法
IL287916B2 (en) 2015-07-30 2023-09-01 Macrogenics Inc Molecules that bind pd-1 and methods of using them
KR20250079249A (ko) 2015-10-08 2025-06-04 마크로제닉스, 인크. 암 치료를 위한 조합 치료법
KR102815803B1 (ko) 2015-12-02 2025-06-05 주식회사 에스티사이언스 당화된 btla(b- 및 t-림프구 약화인자)에 특이적인 항체
SG11201804839WA (en) 2015-12-14 2018-07-30 Macrogenics Inc Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof
WO2017180813A1 (en) 2016-04-15 2017-10-19 Macrogenics, Inc. Novel b7-h3 binding molecules, antibody drug conjugates thereof and methods of use thereof
US10111929B1 (en) 2017-04-07 2018-10-30 Ez Ip, Llc Growth hormone releasing factor analogs and uses
US20220411511A1 (en) 2019-09-26 2022-12-29 Stcube & Co. Antibodies specific to glycosylated ctla-4 and methods of use thereof
KR20220088438A (ko) 2019-10-09 2022-06-27 주식회사 에스티큐브앤컴퍼니 글리코실화된 lag3에 대해 특이적인 항체 및 이의 사용 방법
US11596665B2 (en) 2020-06-23 2023-03-07 Chanda Zaveri Skin lightening formulations
US11951203B2 (en) 2020-08-26 2024-04-09 Chanda Zaveri Deep wrinkle vanishing compositions
US11793746B2 (en) 2020-10-01 2023-10-24 Chanda Zaveri Intense skin hydration systems and methods
US20220110852A1 (en) 2020-10-14 2022-04-14 Chanda Zaveri Pigment Stabilizers

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3904594A (en) * 1973-07-02 1975-09-09 Salk Inst For Biological Studi Somatostatin and acylated des-(ala' 1', gly' 2') derivatives thereof
US3842067A (en) * 1973-07-27 1974-10-15 American Home Prod Synthesis of(des-asn5)-srif and intermediates
US3917578A (en) * 1973-12-10 1975-11-04 Ayerst Mckenna & Harrison Process for producing somatostatin and intermediates
US3882098A (en) * 1974-01-03 1975-05-06 American Home Prod Synthesis of des-Ala{hu 1{b , Gly{hu 2{b , Asn{hu 5{b -SRIF and intermediates
US4011207A (en) * 1974-12-27 1977-03-08 American Home Products Corporation Des-(Ala1, Gly2,Lys4 -Srif, Des-(Ala1, Gly2, Lys4)-D-Trp8 -Srif and intermediates
US3933784A (en) * 1975-01-27 1976-01-20 American Home Products Corporation Des-(ser13)-srif and intermediates

Also Published As

Publication number Publication date
NL7803289A (nl) 1978-10-02
DK131878A (da) 1978-09-29
IE780511L (en) 1978-09-28
BE865380A (fr) 1978-07-17
GB1564191A (en) 1980-04-02
AU519122B2 (en) 1981-11-12
DE2813327C2 (enExample) 1988-08-18
ATA213878A (de) 1981-07-15
IE46862B1 (en) 1983-10-19
IT1105152B (it) 1985-10-28
SE446190B (sv) 1986-08-18
CA1102314A (en) 1981-06-02
JPS53130687A (en) 1978-11-14
CH639361A5 (de) 1983-11-15
ES468241A1 (es) 1978-12-01
LU79320A1 (fr) 1978-06-29
DE2813327A1 (de) 1978-10-05
ZA781599B (en) 1979-10-31
IT7848586A0 (it) 1978-03-23
SE7803318L (sv) 1978-09-29
US4105603A (en) 1978-08-08
JPS6141920B2 (enExample) 1986-09-18
AU3430778A (en) 1979-09-27
FR2385688A1 (fr) 1978-10-27
FI780907A7 (fi) 1978-09-29
FR2385688B1 (enExample) 1983-10-07

Similar Documents

Publication Publication Date Title
AT366026B (de) Verfahren zur herstellung von neuen peptiden
AT353992B (de) Verfahren zur herstellung von neuen peptiden
AT360674B (de) Verfahren zur herstellung von neuen peptiden
AT382625B (de) Verfahren zur herstellung von neuen peptiden
AT372093B (de) Verfahren zur herstellung von neuen corticoid-17- alkylcarbonaten
AT360153B (de) Verfahren zur herstellung von neuen ver- bindungen
AT370090B (de) Verfahren zur herstellung von neuen cyclopeptiden
AT359219B (de) Verfahren zur herstellung von neuen peptiden
LU79212A1 (de) Verfahren zur herstellung von neuen 4-acylamino-phenylaethanolaminen
AT363198B (de) Verfahren zur herstellung von neuen peptidverbindungen
AT371455B (de) Verfahren zur herstellung von neuen prostanderivaten
AT357262B (de) Verfahren zur herstellung von neuen antibiotika
AT368753B (de) Verfahren zur herstellung von neuen azacycloalkanen
AT359660B (de) Verfahren zur herstellung von neuen polypeptiden
AT368137B (de) Verfahren zur herstellung von neuen 4-amino-5alkylthiopyrimidinen
AT366368B (de) Verfahren zur herstellung von neuen chinolylguanidinen
AT361622B (de) Verfahren zur herstellung von neuen anthra- cyclinglycosid-anitbiotika
AT358169B (de) Verfahren zur herstellung von neuen ver- bindungen
AT372690B (de) Verfahren zur herstellung von neuen polyhydantoinen
AT360676B (de) Verfahren zur herstellung von neuen 17beta- -hydroxy-4-androsten-3-onen
ATA750578A (de) Verfahren zur herstellung von neuen pyridothiazo- linen
AT364081B (de) Verfahren zur herstellung von neuen antibiotika
AT359517B (de) Verfahren zur herstellung von neuen alfa- -halogenaethylcarbamidsaeurehalogeniden
ATA68579A (de) Verfahren zur herstellung von neuen peptiden
LU77699A1 (de) Verfahren zur herstellung von neuen d-homosteroiden

Legal Events

Date Code Title Description
ELA Expired due to lapse of time
ELJ Ceased due to non-payment of the annual fee